Takeda Adcetris wins European conditional marketing authorization
Adcetris is indicated for use in adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.